MedTrace Logo

Study to Evaluate the Efficacy and Safety of Colchicine Tablets in Patients With COVID-19

NCT05038449 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2021-09-09

No results posted yet for this study

Summary

This study is designed for single-center, randomized, open label, standard therapy controlled. 60 COVID-19 subjects with a treatment period of 10 days and follow-up until 28 days after enrollment.

Conditions

  • Covid19
  • Colchicine

Interventions

DRUG

Colchicine Tablets

Colchicine Tablets (Each tablet contains colchicine 0.5mg)

DRUG

Standard therapy

Standard therapy for COVID-19 according to the Novel Coronavirus Pneumonia Diagnosis and Treatment Plan (Trial 8th Edition)

Sponsors & Collaborators

  • Kunming Pharmaceuticals, Inc.

    collaborator INDUSTRY

  • Shanghai Public Health Clinical Center

    lead OTHER_GOV

Principal Investigators

  • Hongzhou Lu, PI · Shanghai Public Health Clinical Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-09-06
Primary Completion
2023-06-01
Completion
2023-09-01

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05038449 on ClinicalTrials.gov